Data Year:

For its 2024 fiscal year, Jazz Pharmaceuticals plc, listed the following executives on its annual proxy statement to the SEC

Equity
Cash Compensation
Other
Fiscal Year Ended in 2024
Name And Title Total Compensation Pay Rank By Title In Biotechnology industry
Bruce C. Cozadd
Chairperson and CEO
Total Compensation $15,527,464 View details Pay Rank By Title In Biotechnology industry #49 View more
Renée Galá
President and COO
Total Compensation $6,628,888 View details Pay Rank By Title In Biotechnology industry #12 View more
Robert Iannone M.D., M.S.C.E
Executive Vice President, Global Head of R&D
Total Compensation $5,689,377 View details Pay Rank By Title In Biotechnology industry #36 View more
Patricia Carr
Senior Vice President and CAO (Former Interim Principal Financial Officer)
Total Compensation $1,452,211 View details Pay Rank By Title In Biotechnology industry #224 View more
Samantha Pearce
Executive Vice President, CCO
Total Compensation $4,464,254 View details Pay Rank By Title In Biotechnology industry #50 View more
Philip L. Johnson
Executive Vice President and CFO
Total Compensation $5,243,445 View details Pay Rank By Title In Biotechnology industry #51 View more

The charts on this page feature a breakdown of the total annual pay for the top executives at Jazz Pharmaceuticals plc as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. Jazz Pharmaceuticals plc income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. Jazz Pharmaceuticals plc annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
Bruce C. Cozadd
Chairperson and CEO
Total Cash $2,695,959 Equity $12,799,687 Other $31,818 $15,527,464
Renée Galá
President and COO
Total Cash $1,521,923 Equity $5,079,392 Other $27,573 $6,628,888
Robert Iannone M.D., M.S.C.E
Executive Vice President, Global Head of R&D
Total Cash $1,348,692 Equity $4,317,333 Other $23,352 $5,689,377
Patricia Carr
Senior Vice President and CAO (Former Interim Principal Financial Officer)
Total Cash $650,667 Equity $761,822 Other $39,722 $1,452,211
Samantha Pearce
Executive Vice President, CCO
Total Cash $1,410,794 Equity $2,975,603 Other $77,857 $4,464,254
Philip L. Johnson
Executive Vice President and CFO
Total Cash $1,158,539 Equity $4,063,313 Other $21,593 $5,243,445
For its 2024 fiscal year, Jazz Pharmaceuticals plc, listed the following CEO pay ratio data on its annual proxy statement to the SEC.
CEO Name CEO Pay Median Employee Pay CEO Pay Ratio
Bruce C. Cozadd CEO Pay $15,527,464 Median Employee Pay $281,421 CEO Pay Ratio 55:1
For its 2024 fiscal year, Jazz Pharmaceuticals plc, listed the following board members on its annual proxy statement to the SEC.
Name Total COMPENSATION
Anne O'Riordan Total Cash $523,660
Catherine A. Sohn, Pharm.D. Total Cash $57,308
Heather Ann McSharry Total Cash $542,573
Jennifer E. Cook Total Cash $534,265
Kenneth W. O'Keefe Total Cash $512,573
Laura J. Hamill Total Cash $460,602
Mark D. Smith, M.D. Total Cash $520,073
Norbert G. Riedel, Ph.D. Total Cash $533,179
Patrick G. Enright Total Cash $525,073
Patrick Kennedy Total Cash $675,388
Peter Gray Total Cash $63,038
Rick E. Winningham Total Cash $570,073
Seamus Mulligan Total Cash $530,073
Browse Board of Directors By First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Executives by First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Companies by Company Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

Use of Data / Disclaimer

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

What is a proxy statement?

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.